Myoseverin
Based on 1 Customer Validation
Myoseverin is a microtubule-binding molecule and angiogenesis inhibitor. Myoseverin can induce the reversible fission of multinucleated myotubes into mononucleated fragments. In addition, Myoseverin exerts anti-angiogenic effects by inhibiting endothelial cell function and endothelial progenitor cell differentiation.
For research use only. We do not sell to patients.
- Purity : 99.17%
- CAS No.: 267402-71-1
- Formula: C24H28N6O2
- Molecular Weight:432.52
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10498
LexibulinTubulin Polymerisation Inhibitor -
HY-17029
Epothilone BMicrotubule Stabilizer -
HY-14949
Cevipabulin -
HY-B0015
PaclitaxelAntitumor Agent -
HY-19792
MertansineMicrotubule-Targeted Cytotoxin -
HY-13674
MaytansineMicrotubule/Tubulin Inhibitor -
HY-15584
TaltobulinTubulin Inhibitor -
HY-15579
MMAFTubulin Inhibitor -
HY-17583
GriseofulvinAntifungal Antibiotic -
HY-N0488
Vincristine sulfateAntineoplastic Agent -
HY-B0011
DocetaxelMicrotubule Depolymerization Inhibitor -
HY-13520
NocodazoleMicrotubule Inhibitor
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: Myoseverin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| CCRF-CEM | IC50 |
5.7 μM
Compound: myoseverin
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| HCT-116 | IC50 |
3.3 μM
Compound: myoseverin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| HCT-116 | IC50 |
7.82 μM
Compound: Myoseverin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| HepG2 | IC50 |
3.06 μM
Compound: Myoseverin
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 31610375] |
| MCF7 | IC50 |
11.5 μM
Compound: myoseverin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| MES-SA | IC50 |
8.5 μM
Compound: myoseverin
|
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| SW48 | IC50 |
2.7 μM
Compound: myoseverin
|
Cytotoxicity against human SW48 cells after 72 hrs by MTT assay
Cytotoxicity against human SW48 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| SW480 | IC50 |
4.8 μM
Compound: myoseverin
|
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
|
[PMID: 19349183] |
| U-937 | GI50 |
4 μM
Compound: Myoseverin
|
Growth inhibition of human U937 cells
Growth inhibition of human U937 cells
|
[PMID: 11741468] |
In Vitro
Myoseverin (20 μM; 24 h) promotes the fission of multinucleated myotubes into mononucleated fragments with "bead-on-a-string" constriction morphology, and causes disassembly of the microtubule cytoskeleton with microtubules aggregating around the nucleus and fragmenting in mouse C2C12 myotubes[1].
Myoseverin (20 μM; 24 h) promotes DNA synthesis and colony formation, and regulates the expression of more than 93 genes, involving extracellular matrix remodeling, growth factors, immunomodulatory pathways, etc in mouse C2C12 myotubes[1].
Myoseverin (0-80 μM; 1-7 d) inhibits cell proliferation (IC50: 8 μM) in a reversible manner and suppresses cell migration in human umbilical vein endothelial cells[2].
Myoseverin (0-80 μM; 7 d) reduces the differentiation of endothelial progenitor cells into adherent cells in human cord blood mononuclear cells[2].
Myoseverin (0-20 μM; 7 d) inhibits the acetylated low-density lipoprotein (ac-LDL) uptake ability and the expression of endothelial markers (KDR, CD31, vWF) in endothelial progenitor cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human umbilical vein endothelial cells
-
Concentration:0, 2.5, 5, 10, 20, 40 and 80 μM
-
Incubation Time:72 h
-
Result:Inhibited the cell viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4.5-day-old chick embryos (chorioallantoic membrane (CAM) model was established by normal incubation of eggs)[2]
-
Dosage:0, 0.1, 1, 5 and 10 μg/embryo
-
Administration:Topical application; single dose (48 h)
-
Result:Did not show significant inhibition at low doses (0.1 μg or 1 μg/embryo).
Potently inhibited in vivo angiogenesis by showing a marked inhibition zone around the implanted cover slip without affecting embryo’s viability at 5 μg or 10 μg/embryo.
Chemical Information
-
CAS No. 267402-71-1
-
Appearance Solid
-
Molecular Weight 432.52
-
Formula C24H28N6O2
-
Color Off-white to light yellow
-
SMILES
CC(N1C=NC2=C(NCC3=CC=C(OC)C=C3)N=C(NCC4=CC=C(OC)C=C4)N=C12)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 250 mg/mL (578.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
iPSC cell differentiation
Induced pluripotent stem cells (iPSCs) are a type of cell that has similar properties to embryonic stem cells through somatic cell reprogramming.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rosania GR, et al. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat Biotechnol. 2000;18(3):304-308. [Content Brief]
[2]. Park HE, et al. Myoseverin is a potential angiogenesis inhibitor by inhibiting endothelial cell function and endothelial progenitor cell differentiation. DNA Cell Biol. 2006 Sep;25(9):514-22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3120 mL | 11.5602 mL | 23.1203 mL | 57.8008 mL |
| 5 mM | 0.4624 mL | 2.3120 mL | 4.6241 mL | 11.5602 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3120 mL | 5.7801 mL | |
| 15 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8534 mL | |
| 20 mM | 0.1156 mL | 0.5780 mL | 1.1560 mL | 2.8900 mL | |
| 25 mM | 0.0925 mL | 0.4624 mL | 0.9248 mL | 2.3120 mL | |
| 30 mM | 0.0771 mL | 0.3853 mL | 0.7707 mL | 1.9267 mL | |
| 40 mM | 0.0578 mL | 0.2890 mL | 0.5780 mL | 1.4450 mL | |
| 50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1560 mL | |
| 60 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9633 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7225 mL | |
| 100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.5780 mL |
Myoseverin Related Classifications
HY-W008956 Related Classifications
Powered by Bioz